Trial Profile
QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary) ; Mesalazine (Primary) ; Mesalazine (Primary)
- Indications Ulcerative proctitis
- Focus Therapeutic Use
- Acronyms QUARTZ
- Sponsors Ferring Pharmaceuticals
- 14 Nov 2022 Primary endpoint (Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) total score) has been met, according to Results published in the European Journal of Gastroenterology and Hepatology.
- 14 Nov 2022 Results (n=93) assessing the impact of mesalazine treatment for mild to moderate ulcerative proctitis and proctosigmoiditis on patient quality of life, published in the European Journal of Gastroenterology and Hepatology.
- 13 Oct 2020 Results (n=93) presented at the 28th United European Gastroenterology Week.